<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449163</url>
  </required_header>
  <id_info>
    <org_study_id>20060042</org_study_id>
    <secondary_id>SCCC-2005145</secondary_id>
    <secondary_id>WIRB-20060252</secondary_id>
    <nct_id>NCT00449163</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer</brief_title>
  <official_title>Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor
      growth in different ways. Some block the ability of tumor cells to grow and spread. Others
      find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab
      may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving
      combination chemotherapy together with bevacizumab may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
      with bevacizumab works in treating patients with stage IV colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the purpose of this study treatment cycle consist of six weeks, 2 weeks of consecutive
      treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest.
      Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29 according to
      the schedule. There will be no treatment delivered on weeks 3 &amp; 6 (Days 15 and 36).

      Disease will be evaluated by CT scan at the completion of every two cycles. Patients with
      complete response (CR), or partial response (PR), will be evaluated for possible surgical
      resection. Patients who become operable will continue to be evaluated for survival and
      disease relapse. Patients with stable disease (SD), and those with less than pCR after
      surgery should continue chemotherapy until radiographic evidence of tumor progression is
      identified or unacceptable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated by University of Miami Institutional Review Board
  </why_stopped>
  <start_date type="Actual">March 1, 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival up to 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients with overall survival times of up to 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Complete Response and Partial Response)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival in Months</measure>
    <time_frame>2 years</time_frame>
    <description>Median number of months subjects achieved progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Toxicity in Study Participants</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation the safety and toxicities of protocol regimen as evidenced by the rate of serious adverse events in study participants.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Combination Chemotherapy and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Combination Chemotherapy and Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine</intervention_name>
    <arm_group_label>Combination Chemotherapy and Bevacizumab</arm_group_label>
    <other_name>5-fluorodeoxyuridine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Combination Chemotherapy and Bevacizumab</arm_group_label>
    <other_name>Irinotecan Hydrochloride</other_name>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Combination Chemotherapy and Bevacizumab</arm_group_label>
    <other_name>Leucovorin calcium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have stage IV, histologically confirmed diagnosis of Adenocarcinoma of
             the colon.

          2. Patients must have bi-dimensionally measurable disease since the purpose of this study
             is to determine efficacy of treatment.

          3. Patients must be previously untreated.

          4. Patients must be over the age of 18 years.

          5. Patients may not be pregnant. Patients of childbearing years must be using
             contraception.

          6. Patients must have ECOG performance status of 0-1 or KPS of at least 70.

          7. Patients must have life expectancy of ≥ two months.

          8. Patients must have a white blood cell count of ≥1000/mm³ ANC &gt; 1.0, platelets &gt;
             100,000/mm³.

          9. Patients must have adequate renal function as documented by a serum creatinine of ≤
             1.5 mg/dl.

         10. Patients must have a bilirubin of ≤ 1.5 mg/dl and an SGOT of ≤ three times normal for
             patients with no liver disease, and ≤ five times normal for those with liver
             metastases.

         11. Patients must be informed of the investigational nature of the study and give written
             informed consent.

         12. Patients must have indwelling central venous catheter or good peripheral intravenous
             catheter, preferably a port-a-cath.

         13. Patients may have had prior surgery for their colorectal cancer. Patients must be at
             least 8 weeks beyond surgery and recovered from all effects of surgery.

         14. Patients enrolled in this study may have a history of prior malignancy (5 years ago)
             provided that the patient is currently disease-free.

        Exclusion Criteria:

          1. Patients who have had prior chemotherapy or radiation therapy for their colorectal
             cancer, with exception of adjuvant chemo/radiation therapy.

          2. Patients receiving concomitant radiation, hormonal therapy, chemotherapy, or
             immunotherapy.

          3. Patients receiving any investigational drug within 30 days prior to start of this
             study.

          4. Patients with serious underlying medical illnesses (including Congestive Heart Failure
             New York Heart Association Functional Classification 2-4) or active infection.

          5. Patients with central nervous system metastasis must have completed radiation prior to
             entry into this protocol.

          6. Patients with psychiatric conditions or associated conditions which would make
             participating in this study dangerous to their health.

          7. Patients with uncontrolled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bach Ardalan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ascopubs.org/doi/abs/10.1200/jco.2009.27.15s.e15114</url>
    <description>DOI: 10.1200/jco.2009.27.15s.e15114 Journal of Clinical Oncology 27, no. 15S - published online before print.</description>
  </link>
  <results_reference>
    <citation>Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL) B. Ardalan, M. Feagans, D. Mezentsev, C. Jones, P. R. Subbarayan, G. Walker, M. Sapp, K. Stephenson, J. Ness, D. Franceschi, and A. Livingstone Journal of Clinical Oncology 2009 27:15S, e15114-e15114</citation>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <results_first_submitted>January 23, 2013</results_first_submitted>
  <results_first_submitted_qc>January 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2013</results_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 25 subjects were enrolled however; data were analyzed for only 22 of the subjects enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination Chemotherapy and Bevacizumab</title>
          <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Chemotherapy and Bevacizumab</title>
          <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="38" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival up to 2 Years</title>
        <description>Percentage of patients with overall survival times of up to 2 years</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Chemotherapy and Bevacizumab</title>
            <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival up to 2 Years</title>
          <description>Percentage of patients with overall survival times of up to 2 years</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="27" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (Complete Response and Partial Response)</title>
        <description>Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Chemotherapy and Bevacizumab</title>
            <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete Response and Partial Response)</title>
          <description>Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="43" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival in Months</title>
        <description>Median number of months subjects achieved progression-free survival</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Chemotherapy and Bevacizumab</title>
            <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival in Months</title>
          <description>Median number of months subjects achieved progression-free survival</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="8.4" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Toxicity in Study Participants</title>
        <description>Evaluation the safety and toxicities of protocol regimen as evidenced by the rate of serious adverse events in study participants.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Chemotherapy and Bevacizumab</title>
            <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Toxicity in Study Participants</title>
          <description>Evaluation the safety and toxicities of protocol regimen as evidenced by the rate of serious adverse events in study participants.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only serious adverse events (Grade 3 and 4) reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination Chemotherapy and Bevacizumab</title>
          <description>Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Port Site Thrombosis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A total of 25 subjects were enrolled however; data were analyzed for 22 subjects only. Study was terminated early by the University of Miami Institutional Review Board.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bach Ardalan MD</name_or_title>
      <organization>UM/Sylvester Comprehensive Cancer Center</organization>
      <phone>305-243-4909</phone>
      <email>bardalan@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

